Comparison
NMN vs Alpha-Lipoic Acid
NMN
Nicotinamide mononucleotide, NAD+ precursor. Studied for cellular aging and metabolic health.
Alpha-Lipoic Acid
Universal antioxidant active in both lipid and aqueous environments. Supports mitochondrial function and AGE reduction.
| Field | NMN | Alpha-Lipoic Acid |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 250–1000mg | 300–600mg |
| Half-life | – | 1h |
| Onset | – | – |
| Evidence | EVIDENCEB | EVIDENCEA |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USOTC |
| PubMed refs | 600 | 1900 |
The comparison in plain English
Auto-generated from dataNMN and Alpha-Lipoic Acid are both in the neuroprotective category respectively. NMN Nicotinamide mononucleotide, NAD+ precursor. Alpha-Lipoic Acid Universal antioxidant active in both lipid and aqueous environments.
Bottom line
NMN (evidence B, safety 5/5) has a stronger evidence base than Alpha-Lipoic Acid (evidence A, safety 4/5). NMN has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose NMN if
NMN is the better fit when your goal aligns with its mechanism (Direct precursor to NAD+, one biosynthetic step closer than nicotinamide riboside, bypassing the NRK1/NRK2 enzymatic step) and the dose range (250–1000mg) suits your protocol. Half-life is –h.
Choose Alpha-Lipoic Acid if
Alpha-Lipoic Acid is the better fit when your goal aligns with its mechanism (A 'universal' antioxidant, uniquely active in both lipid (cell membrane) and aqueous (cytoplasm) environments because of its dithiol functional group) and the dose range (300–600mg) suits your protocol. Half-life is 1h.